The company attributes its increase to European sales of its orthoPACE. Research expenses in 2011 were $2.7 million, while general and administrative expensive toped $6.2 million.
Over the past year, the company published preclinical data on its ESWT technology to promote fracture healing and received a patent covering its invention and delivery methods for shock wave therapy treatment. The company also procured two CPT Category III codes for ESWT in wound healing.
Sign up for our FREE Orthopedic E-Weekly for more coverage like this sent to your inbox!
More Articles on Orthopedic Implants:
BioMimetic Reports Revenue Increase in 2011 to $1.7B
17 Spine Devices Receive FDA 510(k) Clearance in February
New Test Will Fight Infection in Hip, Knee Replacements
